Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ILK | Q13418 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 5/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.41 |
| ▸ | PKN2 | Q16513 | 5/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 4/20 | 0.41 |
| ▸ | PRKACA | P17612 | 4/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.41 |
| ▸ | RPS6KA3 | P51812 | 4/20 | 0.41 |
| ▸ | PRKG1 | Q13976 | 4/20 | 0.41 |
| ▸ | CDC42BPA | Q5VT25 | 4/20 | 0.41 |
| ▸ | HIPK4 | Q8NE63 | 4/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.41 |
| ▸ | AKT1 | P31749 | 3/20 | 0.41 |
| ▸ | GSK3A | P49840 | 3/20 | 0.41 |
| ▸ | CSNK1G3 | Q9Y6M4 | 3/20 | 0.41 |
| ▸ | NEK4 | P51957 | 3/20 | 0.41 |
| ▸ | MATK | P42679 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1228940 | 0.86 | RPS6KB1 (0.44) | GSK3BROCK1PKN2AURKBCHEK2 | |
| SCHEMBL1229917 | 0.84 | TTK (0.46) | GSK3BROCK1PKN2AURKBCHEK2 | |
| SCHEMBL1229231 | 0.83 | POLB (0.44) | GSK3BROCK1PKN2AURKBCHEK2 | |
| SCHEMBL4914854 | 0.80 | GSK3B (0.43) | GSK3BROCK1PKN2AURKBCHEK2 | |
| SCHEMBL1229617 | 0.78 | GSK3B (0.45) | GSK3BROCK1PKN2AURKBCHEK2 | |
| SCHEMBL4909188 | 0.75 | CA2 (0.50) | GSK3BROCK1PKN2AURKBCHEK2 | |
| SCHEMBL1228327 | 0.74 | ROCK2 (0.66) | GSK3BROCK1PKN2AURKBCHEK2 | |
| SCHEMBL4598765 | 0.72 | ROCK2 (0.43) | GSK3BROCK1PKN2AURKBCHEK2 | |
| SCHEMBL4598469 | 0.72 | ROCK1 (0.41) | GSK3BROCK1PKN2AURKBCHEK2 | |
| SCHEMBL4916029 | 0.72 | NTRK1 (0.45) | GSK3BROCK1PKN2AURKBCHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130017188-A1 | MODULATION OF SGK1 EXPRESSION IN TH17 CELLS TO MODULATE TH17-MEDIATED IMMUNE RESPONSES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2013-01-17 | — | — | US | claimed |
| EP-2459184-A1 | MODULATION OF SGK1 EXPRESSION IN TH17 CELLS TO MODULATE TH17-MEDIATED IMMUNE RESPONSES | The Brigham and Women's Hospital, Inc. (US) | 2012-06-06 | — | — | EP | claimed |
| WO-2011014775-A1 | MODULATION OF SGK1 EXPRESSION IN TH17 CELLS TO MODULATE TH17-MEDIATED IMMUNE RESPONSES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2011-02-03 | — | — | WO | claimed |
| US-20090036449-A1 | Indazolesquaric Acid Derivatives as Chk1, Chk2 and Sgk Inhibitors | MERCK PATENT GMBH (DE) | 2009-02-05 | — | — | US | claimed |
| EP-1866288-A1 | INDAZOLE SQUARIC ACID DERIVATIVES AS CHK1-, CHK2- AND SGK- INHIBITORS | Merck Patent GmbH (DE) | 2007-12-19 | — | — | EP | claimed |
| WO-2006105865-A1 | INDAZOLE SQUARIC ACID DERIVATIVES AS CHK1-, CHK2- AND SGK- INHIBITORS | MERCK PATENT GMBH (DE) | 2006-10-12 | — | — | WO | claimed |
| US-20130017188-A1 | MODULATION OF SGK1 EXPRESSION IN TH17 CELLS TO MODULATE TH17-MEDIATED IMMUNE RESPONSES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| EP-2459184-A1 | MODULATION OF SGK1 EXPRESSION IN TH17 CELLS TO MODULATE TH17-MEDIATED IMMUNE RESPONSES | The Brigham and Women's Hospital, Inc. (US) | 2012-06-06 | — | — | EP | disclosed |
| WO-2011014775-A1 | MODULATION OF SGK1 EXPRESSION IN TH17 CELLS TO MODULATE TH17-MEDIATED IMMUNE RESPONSES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2011-02-03 | — | — | WO | disclosed |
| US-20090036449-A1 | Indazolesquaric Acid Derivatives as Chk1, Chk2 and Sgk Inhibitors | MERCK PATENT GMBH (DE) | 2009-02-05 | — | — | US | disclosed |
| EP-1866288-A1 | INDAZOLE SQUARIC ACID DERIVATIVES AS CHK1-, CHK2- AND SGK- INHIBITORS | Merck Patent GmbH (DE) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006105865-A1 | INDAZOLE SQUARIC ACID DERIVATIVES AS CHK1-, CHK2- AND SGK- INHIBITORS | MERCK PATENT GMBH (DE) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130017188-A1 | MODULATION OF SGK1 EXPRESSION IN TH17 CELLS TO MODULATE TH17-MEDIATED IMMUNE RESPONSES | SGK1, SGK3, SGK2 | ILK 2019/4885GSK3B 108/4885ROCK1 523/4885 |
| US-20090036449-A1 | Indazolesquaric Acid Derivatives as Chk1, Chk2 and Sgk Inhibitors | CHEK2, CHEK1, SIK2 | ILK 971/4885GSK3B 311/4885ROCK1 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.